-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Innovent Biologics Says NMPA Accepted & Granted Priority Review Designation To NDA For Parsaclisib

Reuters · 01/06/2023 01:34
BRIEF-Innovent Biologics Says NMPA Accepted & Granted Priority Review Designation To NDA For Parsaclisib

- Innovent Biologics Inc 1801.HK:

  • NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA ACCEPTED & GRANTED PRIORITY REVIEW DESIGNATION TO NDA FOR PARSACLISIB

Further company coverage: 1801.HK


((Reuters.Briefs@thomsonreuters.com;))